With this promising view, other dual agonists have been developed, such as ALT-801, which has just concluded a safety assessment in patients, after improving NAFLD characteristics in vivo more than semaglutide or elafibranor [133], or tirzepatide, a novel dual agonist for GIP and GLP-1, approved for T2D therapy in 2022, which is currently being tested for NAFL/NASH, since it seems to also have beneficial effects on the liver [134]. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.